TY - JOUR
T1 - Isolation and Quantification of Methylated Cell-Free DNA in Plasma on an Integrated Microfluidic System
AU - Cheng, Yu Jen
AU - Wang, Chih Hung
AU - Hsu, Keng Fu
AU - Lee, Gwo Bin
N1 - Funding Information:
The authors would like to acknowledge the Ministry of Science and Technology (MOST) of Taiwan (MOST 109-2221-E-007-006-MY3 to G.-B.L.), Taiwan’s National Health Research Institutes (NHRI-EX110-11020EI to G.-B.L. and NHRI-110A1-CACO-02212111) for financial support, and Dr. Yu-Dong Ma and Mr. Yi-Da Chung for providing PCR reagents and valuable discussion.
Publisher Copyright:
©
PY - 2022/2/1
Y1 - 2022/2/1
N2 - Methylated cell-free DNA (cfDNA) has been deemed a promising biomarker for ovarian cancer (OvCa) prognosis and therapy selection. However, exploring the methylation profiles of tumor suppressor genes in cfDNA remains a challenge due to their extremely low concentrations and complicated protocols, as well as methodological constraints. In this study, an integrated microfluidic system was developed to automatically (1) capture methylated cfDNA in plasma by magnetic beads coated with the methyl-CpG-binding domain and (2) quantify the methylation level of tumor suppressor genes by on-chip quantitative polymerase chain reaction (qPCR). For capturing methylated cfDNA from a very small amount of plasma, samples along with beads were mixed in a new micromixer to enhance the capture rate. With a high capture rate (72%) and a limit of quantification of 0.1 pg/μL (3 orders of magnitude lower than that of the benchtop method), the compact system could detect the methylated cfDNA from only 20 μL of plasma sample in 2 h. Furthermore, the dynamic range, from 0.1 to 2000 pg/μL of methylated cfDNA, spans the physiological range in plasma, signifying that this device has great potential for personalized medicine in OvCa.
AB - Methylated cell-free DNA (cfDNA) has been deemed a promising biomarker for ovarian cancer (OvCa) prognosis and therapy selection. However, exploring the methylation profiles of tumor suppressor genes in cfDNA remains a challenge due to their extremely low concentrations and complicated protocols, as well as methodological constraints. In this study, an integrated microfluidic system was developed to automatically (1) capture methylated cfDNA in plasma by magnetic beads coated with the methyl-CpG-binding domain and (2) quantify the methylation level of tumor suppressor genes by on-chip quantitative polymerase chain reaction (qPCR). For capturing methylated cfDNA from a very small amount of plasma, samples along with beads were mixed in a new micromixer to enhance the capture rate. With a high capture rate (72%) and a limit of quantification of 0.1 pg/μL (3 orders of magnitude lower than that of the benchtop method), the compact system could detect the methylated cfDNA from only 20 μL of plasma sample in 2 h. Furthermore, the dynamic range, from 0.1 to 2000 pg/μL of methylated cfDNA, spans the physiological range in plasma, signifying that this device has great potential for personalized medicine in OvCa.
UR - http://www.scopus.com/inward/record.url?scp=85124150121&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124150121&partnerID=8YFLogxK
U2 - 10.1021/acs.analchem.1c04471
DO - 10.1021/acs.analchem.1c04471
M3 - Article
AN - SCOPUS:85124150121
VL - 94
SP - 2134
EP - 2141
JO - Analytical Chemistry
JF - Analytical Chemistry
SN - 0003-2700
IS - 4
ER -